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Abstract
Background: Over the last several decades, as a result of an evolution in manufacturing processes,
a marked development has been made in the field of gonadotropins for ovarian stimulation. Initially,
therapeutic gonadotropins were produced from a simple process of urine extraction and
purification; now they are produced via a complex system involving recombinant technology, which
yields gonadotropins with high levels of purity, quality, and consistency.
Methods: A retrospective analysis of 865 consecutive intracytoplasmic sperm injection (ICSI)
cycles of controlled ovarian hyperstimulation (COH) compared the clinical efficacy of three
gonadotropins (menotropin [hMG; n = 299], highly-purified hMG [HP-hMG; n = 330] and follitropin
alfa [r-hFSH; n = 236]) for ovarian stimulation after pituitary down-regulation. The endpoints were
live birth rates and total doses of gonadotropin per cycle and per pregnancy.
Results: Laboratory and clinical protocols remained unchanged over time, except for the type of
gonadotropin used, which was introduced sequentially (hMG, then HP-hMG, and finally r-hFSH).
Live birth rates were not significantly different for hMG (24.4%), HP-hMG (32.4%) and r-hFSH
(30.1%; p = 0.09) groups. Total dose of gonadotropin per cycle was significantly higher in the hMG
(2685 +/- 720 IU) and HP-hMG (2903 +/- 867 IU) groups compared with the r-hFSH-group (2268
+/- 747 IU; p < 0.001). Total dose of gonadotropin required to achieve clinical pregnancy was 15.7%
and 11.0% higher for the hMG and HP-hMG groups, respectively, compared with the r-hFSH group,
and for live births, the differences observed were 45.3% and 19.8%, respectively.
Conclusion: Although similar live birth rates were achieved, markedly lower doses of r-hFSH
were required compared with hMG or HP-hMG.
Background
Over the last several decades, a marked development has
been made in the field of gonadotropins for ovarian stim-
ulation. This development is the result of an evolution in
manufacturing, with the production of therapeutic gona-
dotropins changing from a simple process of urine extrac-
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tion and purification to a complex system involving
recombinant technology, yielding high levels of purity,
quality, and consistency. Menotropin (human menopau-
sal gonadotropin [hMG]), labeled as a 1:1 ratio of follicle-
stimulating hormone (FSH) and luteinizing hormone
(LH) activity, has been widely used since the 1960s. As the
purification processes became more sophisticated, other
purified gonadotropin products were introduced, includ-
ing a menotropin formulation (highly-purified hMG; HP-
hMG) with the same labeled ratio of FSH:LH activity. In
the 1980s, biotechnology advances resulted in the formu-
lation of a recombinant human FSH (r-hFSH), follitropin
alfa, the first r-hFSH to become available in the market.
Another r-hFSH product, follitropin beta, was also
launched [1]. Due primarily to its safety, efficacy, and
ease-of-use, r-hFSH soon became the preferred gonado-
tropin worldwide for controlled ovarian hyperstimulation
(COH) in the context of in vitro fertilization (IVF) cycles.
In current practice, factors such as efficacy, safety, cost of
the medication, ease of administration, and availability of
product are the determinants of gonadotropin choice.
However, in Brazil and other Latin American countries,
assisted reproductive techniques (ART) and the drugs
used for ovarian stimulation are neither provided by
healthcare plans nor reimbursed by the government.
Thus, patients prefer to purchase lower-cost drugs. In
recent years, our choice of gonadotropin product was
motivated by patient costs and, therefore, we justified the
choice of urinary menotropins for COH in ART proce-
dures. When HP-hMG became available, we recom-
mended this product to our patients. However, in
addition to safety, efficacy, and purity, follitropin alfa, an
r-hFSH product, has a highly consistent isoform profile
and low batch-to-batch variability that may be associated
with a more predictable follicular development [2]. There-
fore, in 2004, we selected r-hFSH as the drug of choice for
COH in intracytoplasmic sperm injection (ICSI) cycles.
The objective of the current analysis was to assess treat-
ment outcomes of ART procedures at our center to com-
pare the efficacy of hMG, HP-hMG, and r-hFSH
(follitropin alfa filled-by-mass [FbM]) for COH after pitu-
itary down-regulation in ICSI cycles.
Methods
Consecutive ICSI cycles (n = 865) performed at Androfert,
a tertiary referral center for male infertility treatment in
Campinas, Brazil, from April 2000 to November 2005
were included in this analysis. Laboratory and clinical
protocols remained unchanged during these time periods,
except for the type of gonadotropin that was sequentially
changed over time, as follows: hMG (Menogon®, Ferring,
Brazil) from April 2000 to February 2002; HP-hMG
(Menopur®, Ferring, Brazil) from March 2002 to January
2004; and r-hFSH (GONAL-f® FbM, Merck Serono, Brazil)
from February 2004 to present. During the considered
period, COH was performed in 299 cycles with hMG; in
330 cycles with HP-hMG; and in 236 cycles with r-hFSH.
Patient cycle data were entered into a database using cus-
tomized software (Androsys®, Androfert-UNIOESTE, Bra-
zil). The overall outcomes of our IVF program have been
consistent during the study period (Table 1).
Signed informed consent was obtained from patients to
use both clinical and laboratory data for analysis. The
analysis was approved by our Institutional Review Board.
Indications for ICSI were in accordance with the guide-
lines of the II Brazilian Consensus of Male Infertility [3],
even if the indication for IVF was a female factor.
Ovarian stimulation
The protocol of ovarian stimulation was the same for all
cycles, except for the gonadotropin product. For all cycles,
treatment was initiated with 400 μg daily intranasal
administration of gonadotropin-releasing hormone ago-
Table 1: Main outcome measures for ANDROFERT, São Paulo reported to REDLARA, 2002-2005* (ICSI cycles only).
2002 2003 2004 2005
Number of cycles† 167 164 151 195
Mean number of transferred embryos per patient 3.3 3.2 3.4 3.3
Clinical pregnancy rate per transfer, % 37.0 46.8 46.7 40.3
Ectopic pregnancy, % 0.7 0.7 2.1 2.6
Spontaneous abortion, % 26.7 19.7 20.6 13.6
Live birth rate, % 28.5 39.7 30.0 30.1
Indication for ICSI, %
Male 26.8 28.2 35.2 32.5
Female 23.0 9.4 24.8 17.2
Both 50.2 62.4 40.0 50.3
*Center began reporting to REDLARA in 2002.
† Total number of ICSI cycles reported is 677 - the cycles prior to 2002, when reporting began, are not included in this table.
ICSI, intracytoplasmic sperm injection; REDLARA, Latin American Registry.Reproductive Biology and Endocrinology 2009, 7:111 http://www.rbej.com/content/7/1/111
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nist (GnRH-a; nafarelin acetate, Synarel®, Zodiac, Brazil),
starting on the twenty-first day of the menstrual cycle and
was maintained until the day before human chorionic
gonadotropin (hCG) administration. For ovarian stimula-
tion, initial daily doses of 150-375 IU of hMG, HP-hMG
or r-hFSH were used and no patients were treated with
combinations of hMG or HP-hMG plus r-hFSH. The ini-
tial dose of gonadotropin was determined by the treating
physician taking into account: age, body mass index,
serum FSH on day 2 or 3 of the menstrual cycle, baseline
ovarian volume on transvaginal ultrasound (TVUS), and
number of pre-antral follicles between days 2 and 3 of the
menstrual cycle after pituitary down-regulation. Ovarian
stimulation commenced only after confirming pituitary
down-regulation by both serum estradiol levels <50 pg/
mL and the absence of ovarian follicles >10 mm in diam-
eter on TVUS.
Ultrasound assessment between the sixth and eighth days
of stimulation was performed to determine if gonadotro-
pin dose adjustments were required; if prevention of ovar-
ian hyper-response was deemed necessary, the dose was
reduced. There was no dose increase of gonadotropin dur-
ing stimulation, even in cases of poor ovarian response.
hCG was administered when two or more ovarian follicles
reached a mean diameter of 18 mm. In the cycles with
hMG and HP-hMG, urine-derived hCG 10,000 IU was
used (Choragon®, Ferring, Brazil), while recombinant
choriogonadotropin 250 μg (Ovidrel® lyophilized, Merck
Serono, Brazil) was used following stimulation with r-
hFSH.
Oocyte retrieval, sperm processing, and IVF
Oocyte retrieval, sperm processing, and IVF were carried
out as previously reported [4-6]. Briefly, oocyte retrieval
was performed under intravenous sedation with propofol
and guided by TVUS, 34-36 hours after hCG administra-
tion. After oocyte aspiration, follicular fluid was examined
for cumulus-corona-oocyte complexes. The complexes
were chemically denuded with 40 IU/mL of hyaluroni-
dase (Hyase®, Vitrolife, Sweden). The isolated oocytes
were then mechanically denuded and classified according
to nuclear maturity. The oocytes were maintained in cul-
ture until sperm microinjection [4].
Spermatozoa obtained by ejaculation were collected after
a 48-72 hour period of ejaculatory abstinence. Sperm
processing was performed by the two-layer discontinuous
colloidal gradient [5]. In the cases of azoospermia, either
testicular sperm aspiration, percutaneous epididymal
sperm aspiration, or testicular sperm extraction using
microsurgery were performed for sperm retrieval [6].
Selection and immobilization of the spermatozoon, and
microinjections, were performed under a 400× magnifica-
tion [4]. The injected oocytes were transferred to a closed
culture system and incubated for 16-18 hours at 37°C and
5.5% CO2, until confirmation of fertilization. Fertiliza-
tion was considered normal when oocytes with two pro-
nuclei were seen.
Embryo culture, transfer, and cleavage check
Fertilized oocytes were maintained in culture until trans-
fer of the embryos to the uterine cavity guided by abdom-
inal ultrasound on the third day of embryo culture. The
embryos were placed 10-15 mm from the fundus of the
uterine cavity.
Embryo cleavage was checked approximately 48 and 72
hours after ICSI and the number, symmetry, and expan-
sion of the blastomeres, multinucleation, anomalies of
the zona pellucida, and the rate of cytoplasmic fragmenta-
tion were recorded. The embryos were classified as top
quality when they had three to four symmetrical blast-
omeres on the second day of culture and seven to eight
symmetrical blastomeres on the third day, with no multi-
nucleation, grade I (no fragmentation) or grade II frag-
mentation (up to 20% of the perivitelline space with
fragments), and no abnormalities in the zona pellucida
[7].
Oocyte collection, micromanipulation of gametes,
embryo culture, and the transfer of embryos to the uterine
cavity were carried out under ISO 6, ISO 5, and ISO 7 envi-
ronments, respectively (VECO, Brazil) [8].
Statistical analysis
All ICSI cycles in our database, within the specified dates,
were included in the analysis, with no inclusion or exclu-
sion criteria. For the analysis of the main outcomes (live
birth rates, and the total doses of gonadotropin per cycle,
per clinical pregnancy, and per live birth), the data were
stratified to the prognostic factors commonly used in
reproductive medicine (age, infertility factor, and number
of prior cycles).
The total population was initially analyzed descriptively.
Besides the main outcomes and the criteria used for strat-
ification, the following outcomes were also evaluated:
duration of stimulation; cancellation rates due to poor
ovarian response (defined as <3 follicles ≥10 mm and/or
a serum estradiol level of <100 pg/mL on stimulation day
7 via ultrasound scan); baseline serum FSH and LH levels
(obtained on days 2 or 3 of the previous menstrual cycle);
serum estradiol levels on the day of hCG administration;
incidence of serious ovarian hyperstimulation syndrome
(OHSS) as per the Golan criteria [9]; number of aspirated
oocytes; number of mature oocytes; rate of fertilization;
percent of top quality embryos (per total number of
embryos obtained); number of transferred embryos;
implantation rates (number of fetal sacs per embryosReproductive Biology and Endocrinology 2009, 7:111 http://www.rbej.com/content/7/1/111
Page 4 of 11
(page number not for citation purposes)
transferred); pregnancy rates; and miscarriage rates. The
main outcomes were analyzed both as a whole and stand-
ardized for age, infertility rate, and number of prior ICSI
cycles.
The qualitative variables were expressed as both absolute
(n) and relative (%) frequencies; the quantitative varia-
bles were means and standard deviations. The Kol-
mogorov-Smirnov test was applied to check the normal
distribution through numeric variables. The relationship
among the variables was evaluated by the Chi-square test.
The analysis of variance for one factor (one-way ANOVA)
was used for the comparison of quantitative variables
when there was a normal distribution of each variable in
the gonadotropin treatment groups. Differences were ana-
lyzed by the Tukey multiple comparisons test. For the var-
iables without normal distribution, comparisons were
performed by the Kruskal-Wallis test and the differences
were compared using the Dunn multiple comparisons
test. A p value of below 0.05 was considered significant.
For each group, the mean total dose of gonadotropin
administered per cycle was divided by both the clinical
pregnancy and live birth rates, in order to define the total
dose of gonadotropin necessary to achieve one pregnancy
or one live birth. Multiple pregnancies were considered as
a single event.
When one gestation produced one live birth and one
abortion, the result was registered as a live birth. It was not
possible to calculate the statistical significance for the nec-
essary doses for achieving pregnancies and live births
among the groups, due to methodological reasons. How-
ever, the differences regarding the gonadotropin doses
used in the subgroups with pregnancies and live births
could be statistically compared among the groups.
Results
The distribution of the 865 ICSI cycles (age, indication,
baseline serum FSH and LH levels, and total number of
ICSI cycles) is presented in Table 2. The mean ± standard
deviation (SD) patient age was significantly lower in the
hMG group (32.5 ± 5.3 years) compared with patients in
the HP-hMG and r-hFSH groups (34.0 ± 4.7 and 34.3 ±
4.8; p < 0.001, respectively). Even after stratification by
patient age groups, 71.2% of patients were ≤35 years old
in the hMG group (mean ± SD age = 29.9 ± 3.7 years),
compared with 60.0% (mean ± SD age = 30.9 ± 3.2 years)
and 60.2% (mean ± SD age = 30.9 ± 3.2 years; p = 0.005)
of the HP-hMG and r-hFSH groups, respectively. In the
>35 years old patient subgroup, the mean ± SD baseline
LH levels were significantly lower in the hMG and r-hFSH
groups (4.2 ± 3.0 and 4.3 ± 3.9, respectively) than in the
HP-hMG group (5.8 ± 4.8; p = 0.004). Baseline FSH was
not significantly different between groups.
Table 2: Baseline details of the 865 ICSI cycles.
hMG
(n = 299)
HP-hMG
(n = 330)
r-hFSH
(n = 236)
p value
Mean age, years (± SD) 32.5 (± 5.3)a 34.0 (± 4.7)b 34.3 (± 4.8)c < 0.001
(a vs b, c)
≤35 years, n (%) 213 (71.2)a 198 (60.0)b 142 (60.2)c 0.005
(a vs b, c)
>35 years, n (%) 86 (28.8)a 132 (40.0)b 94 (39.8)c 0.005
(a vs b, c)
Indication, n (%)
Male factor only 111 (37.1) 99 (30.0) 76 (32.2) 0.27
Mixed factor* 142 (47.5) 156 (47.3) 129 (54.7) 0.19
Female factor 46 (15.4) 75 (22.7) 31 (13.1) 0.33
Treatment cycle, n (%)
1st cycle 195 (65.3) 192 (58.1) 145 (61.4) 0.49
2nd cycle 80 (26.7) 86 (26.0) 60 (25.4) 0.83
≥3rd cycle 24 (8.0) 52 (15.9) 31 (13.2) 0.34
Mean baseline FSH, IU/L (± SD) 6.3 (± 3.2) 6.7 (± 3.7) 6.5 (± 2.8) 0.33
≤35 years 6.0 (± 2.8) 6.5 (± 3.1) 6.1 (± 3.0) 0.23
>35 years 7.2 (± 3.9) 7.2 (± 4.4) 7.3 (± 4.7) 0.69
Mean baseline LH, IU/L (± SD) 4.9 (± 4.1) 5.4 (± 4.4) 5.2 (± 3.7) 0.23
≤35 years 5.2 (± 4.4) 5.2 (± 4.1) 5.1 (± 3.9) 0.63
>35 years 4.2 (± 3.0)a 5.8 (± 4.8)b 4.3 (± 3.9)c 0.004
(b vs a, c)
Distribution by menotropin (hMG), highly-purified menotropin (HP-hMG) or follitropin alfa (r-hFSH), after pituitary down-regulation, in relation to 
the age, indication, baseline FSH and LH levels, and total number of treated cycles.
*Mixed factor: male + female.
FSH, follicle stimulating hormone; hMG, human menopausal gonadotropin; HP-hMG, highly-purified hMG; ICSI, intracytoplasmic sperm injection; 
LH, luteinizing hormone; r-hFSH, recombinant human FSH; SD, standard deviation.Reproductive Biology and Endocrinology 2009, 7:111 http://www.rbej.com/content/7/1/111
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The clinical and laboratory outcomes are provided in
detail in Table 3. The length of stimulation was signifi-
cantly shorter in the hMG group in comparison with the
other groups, both for the total group and the age-strati-
fied subgroups. On the day of hCG administration, the
serum estradiol levels were significantly different between
the different gonadotropin product groups and for the
age-stratified subgroups as well. On the other hand, the
number of metaphase II oocytes in patients >35 years of
age treated with hMG was significantly lower when com-
pared with the other treatment groups. The percentage of
top quality embryos available for transfer was signifi-
cantly higher in the HP-hMG group, both for the total
group and the subgroup ≤35 years of age. The cancellation
rates due to poor ovarian response and the incidence of
serious OHSS did not differ among the groups.
Table 3: Clinical and laboratory outcomes of COH during the 865 ICSI cycles.
hMG
(n = 299)
HP-hMG
(n = 330)
r-hFSH
(n = 236)
p value
Mean length of stimulation, days (± SD) 9.6 (± 1.3)a 10.0 (± 1.3)b 10.1 (± 1.0)c < 0.001
(a vs b, c)
≤35 years 9.5 (± 1.3)a 9.9 (± 1.2)b 10.0 (± 0.9)c < 0.001
(a vs b, c)
>35 years 9.8 (± 1.4)a 10.2 (± 1.6)b 10.2 (± 1.1)c 0.007
(a vs b, c)
Gonadotropin dose adjustment, n (%) 56 (18.7)a 67 (20.3)b 126 (53.4)c < 0.001
(c vs a, b)
≤35 years 43 (20.1)a 47 (23.7)b 90 (63.3)c < 0.001
(c vs a, b)
>35 years 13 (15.1)a 20 (15.1)b 36 (38.2)c < 0.001
(c vs a, b)
Mean estradiol on day of hCG, pg/mL (± SD) 1967.0
(± 1241.0)a
2479.0
(± 1708.0)b
2159.3 (± 1411.7)c 0.001
(a vs b, c)
≤35 years 2174.8
(± 1224.4)a
2609.3
(± 1632.0)b
2392.3
(± 1422.3)c
0.035
(a vs b)
>35 years 1432.7
(± 1124.6)a
2285.1
(± 1804.4)b
1789.1
(± 1325.7)c
0.001
(a vs b)
Cancellation rate, n (%) 23 (7.7) 21 (6.4) 17 (7.2) 0.80
≤35 years 10 (4.7) 9 (4.5) 10 (7.0) 0.50
>35 years 13 (15.1) 12 (9.0) 7 (7.4) 0.20
Severe OHSS, n (%) 7 (2.3) 6 (1.8) 3 (1.3) 0.76
≤35 years, n 5 4 3 -
>35 years, n 2 2 0 -
Mean number of retrieved oocytes, n (± SD) 10.9 (± 6.8) 10.7 (± 6.5) 10.8 (± 6.7) 0.97
≤35 years 12.3 (± 6.7) 11.3 (± 5.5) 11.7 (± 6.0) 0.50
>35 years 7.5 (± 5.8) 9.7 (± 7.6) 9.5 (± 7.5) 0.08
Mean MII oocytes, n (± SD) 8.9 (± 5.6) 8.9 (± 5.7) 8.7 (± 5.6) 0.82
≤35 years 10.1 (± 5.5) 9.4 (± 4.8) 9.1 (± 5.0) 0.20
>35 years 5.8 (± 4.4)a 8.3 (± 6.8)b 8.1 (± 6.3)c 0.01
(a vs b, c)
Fertilization rate 2PN, % (± SD) 72 (± 25) 72 (± 22) 71 (± 23) 0.83
≤35 years 71 (± 22) 72 (± 22) 72 (± 22) 0.76
>35 years 73 (± 30) 72 (± 24) 70 (± 25) 0.20
Top quality embryos on day3, % (± SD) 40 (± 30)a 47 (± 31)b 39 (± 29)c 0.004
(b vs a, c)
≤35 years 41 (± 29)a 47 (± 28)b 39 (± 28)c 0.03
(b vs a, c)
>35 years 39 (± 34) 48 (± 34) 37 (± 30) 0.08
Mean number of transferred embryos, n (± SD) 3.4 (± 1.6) 3.4 (± 1.5) 3.2 (± 1.6) 0.18
≤35 years 3.5 (± 1.4) 3.5 (± 1.4) 3.2 (± 1.4) 0.05
>35 years 2.9 (± 1.9) 3.1 (± 1.6) 3.2 (± 1.8) 0.50
Distribution by menotropin (hMG), highly-purified menotropin (HP-hMG) or follitropin alfa (r-hFSH) for COH. Overall and age-stratified outcomes 
are presented.
2PN, two pronuclei; COH, controlled ovarian hyperstimulation; human chorionic gonadotropin; hMG, human menopausal gonadotropin; HP-hMG, 
highly-purified hMG; ICSI, intracytoplasmic sperm injection; MII, metaphase II; OHSS, ovarian hyperstimulation syndrome; r-hFSH, recombinant 
human follicle-stimulating hormone; SD, standard deviation.Reproductive Biology and Endocrinology 2009, 7:111 http://www.rbej.com/content/7/1/111
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The clinical pregnancy rates per initiated cycle, implanta-
tion and live birth rates per initiated cycle were not statis-
tically different among the groups (Table 4). However, the
differences seen in the live birth rates were in favor of the
r-hFSH and HP-hMG groups, for both the total popula-
tion (p = 0.09) and the subgroup of patients ≤35 years of
age (p = 0.08; Table 4), although these differences were
not statistically significant. After stratification for indica-
tion and number of ICSI attempts, there was no difference
in the live birth rates among the groups (data not shown,
p = 0.16). The incidence of spontaneous abortion was sig-
nificantly higher in the hMG group compared with the
other groups (p = 0.009), mainly due to the subgroup of
patients >35 years of age (Table 4).
The clinical and laboratory outcomes of cycles with clini-
cal pregnancy are provided in Table 5. The mean ± SD
patient age and the length of stimulation were signifi-
cantly lower in the hMG group compared with the other
groups, both for the total group (p = 0.01) and for the age-
stratified subgroup ≤35 years (p = 0.004 and p = 0.001,
respectively). On the day of hCG administration, serum
estradiol was significantly different between the hMG and
HP-hMG groups (p = 0.005) and for all gonadotropin
products in the ≤35 years subgroup as well (p = 0.01). The
percentage of top quality embryos available for transfer
on day 3 was significantly higher in the HP-hMG group,
both for the total group (p = 0.004) and the ≤35 years sub-
group (p = 0.02). Baseline FSH and LH levels, mean
number of retrieved and mature oocytes, fertilization rate,
and the mean number of transferred embryos were not
significantly different between groups.
The distribution of live birth cycles in relation to parity,
gestational age, and birth weight are shown in Table 6.
Singleton births were seen in 68.5%, 63.5%, and 64.8% of
live birth cycles in the hMG, HP-hMG and r-hFSH groups,
respectively. Significant differences were observed for the
gestational age, in the three parity stratifications, in favor
of the r-hFSH group compared with the hMG group. In
the case of twins and triplets, the difference was significant
versus the r-hFSH group (p = 0.03). For triplets, the birth
weight was significantly higher in the r-hFSH group versus
the hMG group (p = 0.03).
The gonadotropin dose used per cycle was significantly
lower in the r-hFSH group compared with the other
groups, for both the overall population (p < 0.001) and
the stratified subgroups (p < 0.001 and p = 0.02 for the
≤35 years and >35 years subgroups, respectively) (Table
7). These differences were also significant for r-hFSH after
stratifying for the cause of infertility (male and mixed fac-
tors) and for the number of treatment cycles. Taking into
account only the cycles that resulted in clinical pregnancy
and live birth, the mean total doses of gonadotropins used
for ovarian stimulation were significantly lower for the r-
hFSH group in comparison with the hMG and HP-hMG
groups.
Table 4: Pregnancy outcomes of the 865 ICSI cycles.
hMG
(n = 299)
HP-hMG
(n = 330)
r-hFSH
(n = 236)
p value
Clinical pregnancy per initiated cycle, n (%) 106 (35.5) 132 (40.0) 82 (34.7) 0.35
≤35 years 84 (39.4) 94 (47.5) 59 (41.5) 0.24
>35 years 22 (25.6) 38 (28.8) 23 (24.5) 0.74
Implantation rate, % (± SD) 16 (24) 20 (27) 16 (23) 0.18
≤35 years 17 (25) 24 (29) 20 (25) 0.15
>35 years 11 (21) 12 (21) 9 (17) 0.61
Ectopic pregnancy, n (%) 1 (0.3) 6 (1.8) 2 (0.8) -
≤3 5  y e a r s 131 -
> 3 5  y e a r s 031 -
Spontaneous abortion,*
n (%)
33 (31.1)a 25 (18.9)b 11 (13.4)c 0.009
(a vs b, c)
≤35 years 21 (25.0) 16 (17.0) 7 (11.9) 0.12
>35 years 12 (54.5)a 9 (23.6)b 4 (17.3)c 0.01
(a vs b, c)
Live birth per initiated cycle, n(%) 73 (24.4) 107 (32.4) 71 (30.1) 0.09
≤35 years 63 (29.5) 78 (39.4) 52 (36.6) 0.08
>35 years 10 (11.6) 29 (21.9) 19 (20.2) 0.21
Clinical pregnancy per initiated cycle, implantation, ectopic pregnancy and spontaneous abortion rates, and live birth per initiated cycle in 865 ICSI 
cycles with menotropin (hMG), highly-purified menotropin (HP-hMG) or follitropin alfa (r-hFSH) used for COH. Overall and age-stratified 
outcomes are presented.
*Spontaneous abortion rates are per clinical pregnancies.
COH, controlled ovarian hyperstimulation; hMG, human menopausal gonadotropin; HP-hMG, highly-purified hMG; ICSI, intracytoplasmic sperm 
injection; r-hFSH, recombinant human follicle-stimulating hormone; SD, standard deviation.Reproductive Biology and Endocrinology 2009, 7:111 http://www.rbej.com/content/7/1/111
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Gonadotropin dose adjustments were performed more
often in the r-hFSH group (53.4%) than in the hMG
(18.7%) and HP-hMG (20.3%) groups (p < 0.001; Table
3). The total dose of gonadotropin to achieve a pregnancy
with a live birth was significantly higher in the hMG and
HP-hMG compared with the r-hFSH group (p = 0.02;
Table 8). The necessary dose of hMG to achieve a preg-
nancy was 15.7% higher than the r-hFSH dose, while the
necessary dose of HP-hMG was 11% higher. These differ-
ences were still higher when considering the live birth
parameter (45.3% and 19.8%, for hMG and HP-hMG,
respectively) (Table 9). Because relative differences
obtained from the rates cannot be statistically compared,
it was not possible to calculate whether these differences
were significant.
Discussion
IVF is a highly complex procedure. Before clinical preg-
nancy and live birth can be achieved, several critical steps
are required, including the ovarian stimulation regimen.
Table 5: Clinical and laboratory outcomes of COH in ICSI cycles with clinical pregnancy during the 865 cycles.
hMG
(n = 106)
HP-hMG
(n = 132)
r-hFSH
(n = 82)
p value
Mean age, years (± SD) 31.1 (± 5.0)a 32.7 (± 4.2)b 32.8 (± 4.2)c 0.01
(a vs b, c)
≤35 years (± SD) 29.2 (± 3.6)a 30.7 (± 3.1)b 30.8 (± 2.9)c 0.004
(a vs b, c)
>35 years (± SD) 38.3 (± 1.9)a 37.0 (± 2.0)b 37.3 (± 1.6)c 0.04
(a vs b, c)
Mean length of stimulation, days (± SD) 9.6 (± 1.3)a 9.8 (± 1.0)b 10.0 (± 1.0)c 0.01
(a vs b, c)
≤35 years 9.5 (± 1.3)a 9.9 (± 1.0)b 10.0 (± 0.9)c 0.001
(a vs b, c)
>35 years 10.1 (± 1.3)a 9.7 (± 1.0)b 9.9 (± 1.0)c 0.66
Mean baseline FSH, IU/L (± SD) 6.0 (± 2.4) 6.5 (± 3.7) 6.3 (± 2.2) 0.63
≤35 years 5.8 (± 2.2) 6.2 (± 2.9) 6.0 (± 2.0) 0.51
>35 years 6.6 (± 3.2) 7.1 (± 5.0) 7.1 (± 4.5) 0.91
Mean baseline LH, IU/L (± SD) 5.6 (± 5.3) 5.5 (± 3.7) 5.2 (± 3.0) 0.90
≤35 years 5.7 (± 5.6) 5.5 (± 4.0) 5.3 (± 4.1) 0.89
>35 years 5.2 (± 3.5) 5.4 (± 2.7) 5.5 (± 3.1) 0.70
Mean estradiol on day of hCG, pg/mL (± SD) 2102.8
(± 1207.4)a
2682.9
(± 1440.7)b
2488.0 (± 1630.7)c 0.005
(a vs b)
≤35 years 2225.5
(± 1221.0)a
2753.3
(± 1402.3)b
2742.9
(± 1716.8)c
0.01
(a vs b, c)
>35 years 1605.7
(± 1036.6)
2510.7
(± 1537.5)
1850.9
(± 1203.6)
0.06
Mean number of retrieved oocytes, n (± SD) 12.1 (± 6.6) 12.2 (± 6.1) 12.4 (± 6.8) 0.92
≤35 years 13.0 (± 6.7) 12.4 (± 5.2) 12.3 (± 5.9) 0.92
>35 years 8.7 (± 5.1) 11.5 (± 8.0) 12.5 (± 9.0) 0.25
Mean MII oocytes, n (± SD) 9.7 (± 4.8) 10.3 (± 5.5) 9.9 (± 5.5) 0.67
≤35 years 10.6 (± 4.8) 10.3 (± 4.6) 9.7 (± 4.6) 0.20
>35 years 6.4 (± 3.1) 10.1 (± 7.3) 10.6 (± 7.3) 0.05
Fertilization rate 2PN, % (± SD) 77 (± 17) 76 (± 17) 75 (± 18) 0.71
≤35 years 74 (± 17) 74 (± 17) 75 (± 17) 0.91
>35 years 88 (± 12) 79 (± 18) 76 (± 19) 0.07
Top quality embryos on day3, % (± SD) 47 (± 28)a 55 (± 28)b 41 (± 25)c 0.004
(b vs a, c)
≤35 years 49 (± 26)a 54(± 28)b 40 (± 26)c 0.02
(b vs c)
>35 years 40 (± 32)a 60 (± 29)b 44 (± 22)c 0.02
(b vs a, c)
Mean number of transferred embryos, n (± SD) 3.9 (± 1.0) 3.8 (± 0.9) 3.6 (± 0.9) 0.65
≤35 years 3.4 (± 1.0) 3.6 (± 0.9) 3.5 (± 0.9) 0.79
>35 years 4.0 (± 0.9) 4.0 (± 0.8) 3.9 (± 0.9) 0.33
Distribution by menotropin (hMG), highly-purified menotropin (HP-hMG) or follitropin alfa (r-hFSH) for COH. Overall and age-stratified outcomes 
are presented.
2PN, two pronuclei; COH, controlled ovarian hyperstimulation; FSH, follicle-stimulating hormone; hCG, human chorionic gonadotropin; hMG, 
human menopausal gonadotropin; HP-hMG, highly-purified hMG; ICSI, intracytoplasmic sperm injection; LH, luteinizing hormone; MII, metaphase II; 
r-hFSH, recombinant human FSH; SD, standard deviation.Reproductive Biology and Endocrinology 2009, 7:111 http://www.rbej.com/content/7/1/111
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In this context, it is vital to evaluate these outcomes in
routine clinical practice to account for subtle differences
in patient response. As a rule, comparative, prospective
and randomized clinical trials are the gold standard to
evaluate the efficacy and safety of a therapy. However,
some of these trials are not statistically powered to show
relevant clinical differences between treatments. Moreo-
ver, strict inclusion and exclusion criteria are required,
which do not represent the heterogeneous patient popu-
lation typically encountered in clinical practice. Another
important consideration is that many ART studies use the
clinical pregnancy rate as the primary efficacy endpoint
instead of live births. However, the latter may be difficult
Table 6: Live birth outcomes of the 865 ICSI cycles.
hMG HP-hMG r-hFSH p value
Cycles with live births, n 73 107 71
Single, n (%) 50 (68.5) 68 (63.5) 46 (64.8) 0.57
Twins, n (%) 18 (24.7) 34 (31.8) 22 (31.0) 0.59
Triplets, n (%) 5 (6.8) 5 (4.7) 3 (4.2) 0.89
Mean gestational age, weeks (± SD)
Single 36.5 (± 3.6)a 38.1 (± 2.1)b 38.3 (± 2.3)c 0.01
(a vs b, c)
Twins 35.0 (± 0.8)a 35.1 (± 3.0)b 37.3 (± 2.7)c 0.03
(a, b vs c)
Triplets 29.3 (± 3.5)a 31.1 (± 3.4)b 34.0 (± 0.0)c 0.03
(a vs c)
Mean weight, g (± SD)
Single 2882 (± 703) 3064 (± 470) 3024 (± 334) 0.09
Twins 2352 (± 436)a 2067 (± 614)b 2230 (± 715)c 0.01
(a vs b)
Triplets 1250 (± 329)a 1470 (± 448)b 1747 (± 196)c 0.03
(a vs c)
Cycles with live births in relation to the parity and gestational outcomes of the babies from 865 ICSI cycles with menotropin (hMG), highly-purified 
menotropin (HP-hMG) or follitropin alfa (r-hFSH) used for COH. Overall and parity-stratified outcomes are presented.
COH, controlled ovarian hyperstimulation; hMG, human menopausal gonadotropin; HP-hMG, highly-purified hMG; ICSI, intracytoplasmic sperm 
injection; r-hFSH, recombinant human follicle-stimulating hormone; SD, standard deviation.
Table 7: Total gonadotropin dose requirements of the 865 ICSI cycles.
hMG
(n = 299)
HP-hMG
(n = 330)
r-hFSH
(n = 236)
p value
Total dose, IU 2685 (± 720)a 2903 (± 867)b 2268 (± 747)c < 0.001
(a, b vs c)
Age:
≤35 years 2558 (± 679)a 2678 (± 739)b 2062 (± 681)c <0.001
(a, b vs c)
>35 years 3002 (± 725)a 3240 (± 935)b 2783 (± 738)c 0.02
(a, b vs c)
Indication:
Male factor 2582 ± 641a 2777 ± 859b 2305 ± 606c 0.003
(a, b vs c)
Mixed factor 2710 ± 751a 2911 ± 892b 2439 ± 770c 0.02
(a, b vs c)
Number of cycles:
1 2690 ± 640a 2816 ± 791b 2374 ± 647c 0.003
(a, b vs c)
2 2670 ± 699a 2942 ± 1,025b 2492 ± 856c 0.003
(a, b vs c)
≥3 2601 ± 803a 3071 ± 887b 2486 ± 800c 0.006
(a, b vs c)
Per cycle data are presented by menotropin (hMG), highly-purified menotropin (HP-hMG) or follitropin alfa (r-hFSH). The number of cycles, 
indication and age-stratified data are shown (mean [± SD]).
hMG, human menopausal gonadotropin; HP-hMG, highly-purified hMG; ICSI, intracytoplasmic sperm injection; r-hFSH, recombinant human follicle-
stimulating hormone; SD, standard deviation.Reproductive Biology and Endocrinology 2009, 7:111 http://www.rbej.com/content/7/1/111
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to evaluate if pregnancy outcome data are not readily
available.
The current analysis examined the clinical efficacy of three
different gonadotropins used for COH in ICSI cycles. In
our program, clinical and laboratory data are systemati-
cally and continually entered into our patient database
and managed by software specially developed for assisted
reproduction programs (Androsys®, Brazil). Clinical fol-
low up of pregnancies is carried out twice per month.
With confirmation of live birth, follow up continues with
the registration of gestational ages, birth weights, neonatal
disorders, and eventual malformations for a period of 30
days post delivery. Using the Androsys® database, it was
possible to compare COH regimens in more than 860
consecutive ICSI cycles at a single ART center. To our
knowledge, this is one of the most comprehensive com-
parative analyses examining both the live birth rates and
the total gonadotropin dose needed per cycle resulting in
clinical pregnancy and live birth. Additionally, our COH
regimens consisted of the respective gonadotropin prod-
ucts (hMG, HP-hMG, and r-hFSH) administered as single
agents, that is, combination protocols of hMG or HP-
hMG plus r-hFSH were not used, a clinical approach that
is widely utilized elsewhere.
Due to the retrospective, observational design of this anal-
ysis, the possibility of some inherent bias exists, although
the non-selected patient population was representative of
the therapeutic profile observed in current clinical prac-
tice. Outcomes were analyzed on an overall basis and
stratified according to acknowledged prognostic parame-
ters commonly used in reproductive medicine (age, infer-
tility factor, and number of treatment attempts) to
account for potential bias. For example, demographic
characteristics were not homogeneous across the patient
population. In fact, the mean age of the menotropin
(hMG) group was significantly lower (1.5 years on aver-
age) and baseline LH values were significantly higher in
the HP-hMG group than in the other groups. Moreover,
more than 70% of the patients treated in the hMG group
were aged ≤35 years versus approximately 60% in the
other two groups. This could explain the shorter duration
of stimulation observed in this group as compared with
the HP-hMG and r-hFSH groups.
The three treatment groups showed similar live birth rates
independent of the gonadotropin used for COH,
although a trend towards higher live birth rates was
observed in the r-hFSH and hMG-HP groups, in both the
overall population and the subgroup aged ≤35 years. In
2004, Ludwig et al. published their analysis of more than
20,000 cycles from the IVF National Registers in Germany
and found that live birth rates were 16.6% higher with r-
hFSH compared with hMG when used for COH after pitu-
itary down-regulation [10]. In their analysis, however, the
Table 8: Total gonadotropin dose requirement to achieve clinical pregnancy/live birth in the 865 ICSI cycles.
hMG HP-hMG r-hFSH p value
Cycles with clinical pregnancy, IU 2519
(± 684)a
2655
(± 612)b
2237
(± 582)c
0.002
(a, b vs c)
Cycles with live birth, IU 2515
(± 613)a
2651
(± 614)b
2243
(± 589)c
0.02
(a, b vs c)
Total dose of menotropin (hMG), highly-purified menotropin (HP-hMG) and follitropin alfa (r-hFSH) used per cycle resulting in a clinical pregnancy 
(n = 320) and per cycle resulting in a live birth (n = 251) (mean [± SD]).
hMG, human menopausal gonadotropin; HP-hMG, highly purified hMG; ICSI, intracytoplasmic sperm injection; r-hFSH, recombinant human follicle-
stimulating hormone; SD, standard deviation.
Table 9: Mean gonadotropin doses required to achieve clinical pregnancy/live birth in the 865 ICSI cycles.
hMG HP-hMG r-hFSH Relative difference, %
hMG vs r-hFSH HP-hMG vs r-hFSH
Dose per clinical pregnancy, IU* 7563 7258 6536 15.7 11
≤35 years 7202 6695 5942 21.2 12.7
>35 years 8456 8100 8020 5.4 1
Dose per live birth, IU* 10,170 8390 7000 45.3 19.8
≤35 years 9690 7739 6364 52.2 21.6
>35 years 11,371 9364 8589 32.4 9
Mean gonadotropin doses required to achieve one clinical pregnancy or one live birth are presented, with relative differences for hMG and HP-
hMG compared with r-hFSH.
*Calculated as the mean dose per cycle/clinical pregnancy rate or live birth rate.
hMG, human menopausal gonadotropin; HP-hMG, highly purified hMG; ICSI, intracytoplasmic sperm injection; r-hFSH, recombinant human follicle-
stimulating hormone.Reproductive Biology and Endocrinology 2009, 7:111 http://www.rbej.com/content/7/1/111
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authors did not evaluate the results stratified by the type
of hMG (conventional or purified), although the differ-
ences favoring r-hFSH remained even after stratification
for several prognostic parameters, including age. In a post-
hoc analysis of a prospective, randomized trial, Platteau et
al. observed that HP-hMG was associated with signifi-
cantly higher live birth rates than r-hFSH when used for
COH in classic IVF cycles, although they reported similar
efficacy in ICSI cycles [11]. However, when evaluated in a
prospective, randomized IVF trial, there was no significant
difference in ongoing pregnancy rates between HP-hMG
and r-hFSH [12].
Although live birth rates were similar among the three
treatment groups, the spontaneous abortion rate was sig-
nificantly higher in the hMG group (Table 4). However,
the significant difference in spontaneous abortion rates
occurred only in the subgroup of women aged >35 years.
One possible explanation was the finding that the mean
age was significantly higher (1.0 years on average) in the
hMG subgroup of women aged > 35 years compared with
the other groups (Table 5).
In Brazil, the acquisition cost of r-hFSH is about 40-50%
more expensive than the urinary menotropins; until now,
this was an argument that supported the choice of urinary
menotropins for COH. However, in our analysis, signifi-
cantly lower doses of follitropin alfa per ICSI cycle were
required to achieve similar clinical pregnancy and live
birth rates. This observation was valid for the overall pop-
ulation as well as for the subgroups stratified for age, indi-
cation, and number of treatment attempts. Moreover,
significantly higher doses of both menotropin products
were necessary per pregnancy and per each live birth (20-
45% higher) when compared with r-hFSH.
The explanations for these findings may relate to differ-
ences in the gonadotropin products due to improved
processes available through utilization of recombinant
technologies [13,14]. Manufacturing improvements have
resulted in significantly improved purity and specific
activity, as well as batch-to-batch consistency of the folli-
tropin alfa drug substance [14,15]. Indeed, in clinical tri-
als, increased efficiency was observed with follitropin alfa
FbM in terms of a lower total dose and shorter treatment
period when compared with FSH products [16-19]. Also,
as noted in the Methods, we routinely utilize a step-down
ovarian stimulation protocol to avoid ovarian hyper-
response. Because of the product improvements inherent
with the follitropin alfa product, our clinicians are confi-
dent that dose adjustments with a decrement of 37.5 IU
are clinically effective. The clinical effectiveness of 37.5 IU
dosing has not been similarly demonstrated with either of
the hMG products.
Conclusion
Similar live birth rates were achieved with hMG, HP-hMG
and r-hFSH when used for COH after pituitary down-reg-
ulation with GnRH-a in ICSI cycles. Significantly lower
total doses of r-hFSH were administered per cycle, com-
pared with the menotropin products. Per each live birth,
considerably higher doses of hMG and HP-hMG (45.3%
and 19.8%, respectively) were used for ovarian stimula-
tion. Thus, the greater purity and consistency of the r-
hFSH FbM formulation resulted in higher treatment effi-
ciency than urine-derived gonadotropins in terms of clin-
ical pregnancy rates and live births.
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